Methods | The study design has been described elsewhere. 3 Briefly, this is a closed, population-based prospective cohort to 9 primary care centers (PCCs) in Tarragona, Spain, who were prospectively followed from December 2008 until November 2011. The PCC's electronic clinical record system was used to classify cohort members by their pneumococcal vaccination status as well as to identify baseline characteristics and underlying conditions of the cohort at study start. Primary outcomes were hospitalization for CAP, AMI, and ischemic stroke.
Community-acquired pneumonia-related episodes of AMI/ stroke were considered when they occurred within 30 days after CAP diagnosis. Outcomes were initially identified on the basis of hospital discharge International Classification of Diseases, Ninth Revision, diagnosis codes for pneumonia (codes 480-487.0), myocardial infarction (code 410), and ischemic stroke (codes 433, 434, 436, and 437). Hospital clinical records were reviewed by a physician for all presumptive cases; only physician-verified diagnoses were included.
Pneumococcal vaccination status was determined by a review of the PCC's clinical records, which contain specially designated fields for pneumococcal and influenza vaccinations (virtually all of them are administered at the PCCs in the Span-ish health system). At the beginning of the study, cohort members were classified as vaccinated against pneumococcus if they had received at least 1 dose of PPV23 within 5 years before the study started. Across the study period, pneumococcal vaccination status was a time-varying condition given that some individuals received PPV23 after the study start.
Cox regression models were used to assess the association between having received PPV23 and the time to the first outcome. We modeled separate analyses: first, to adjust for potential confounding by indication, we estimated PPV23 effectiveness adjusted by propensity score for vaccination (eTable in Supplement); second, we performed classical multivariate analysis adjusted for age, sex, influenza vaccination, and underlying conditions.
Results | Cohort members were followed for a total of 76 033 person-years, of which 29 065 person-years corresponded to immunized individuals. Vaccinated persons were slightly older, had a higher proportion of influenza vaccination, and had more comorbidities than nonvaccinated individuals ( Table 1) .
A first episode of CAP occurred in 566 persons; AMI in 359 (16 were CAP-related episodes); and ischemic stroke in 343 (4 were CAP-related episodes). Incidence rates (per 1000 personyears) were 7.51 for CAP (7.19 vs 7.71 among vaccinated and unvaccinated individuals, respectively), 4.75 for AMI (4.74 vs 4.75), and 4.53 for ischemic stroke (4.60 vs 4.49).
Supplemental content at jamainternalmedicine.com Abbreviations: CAD, coronary artery disease; CHD, chronic heart disease; HR, hazard ratio. a Hazard ratios are for vaccinated as compared with unvaccinated individuals.
Final models were adjusted for epidemiologically relevant, significant and confounder covariates and interactions as appropriate. b Model adjusted for propensity score in quintiles. c Adjusted for age (P < .001), sex (P < .001), influenza vaccine status (P = .10), visits in prior 12 months (P < .001), nursing home residence (P < .001), history of pneumonia (P < .001), history of CAD (P = .02), history of stroke (P < .001), chronic pulmonary disease (P < .001), CHD (P < .001), chronic nephropathy (P < .001), diabetes mellitus (P = .04), smoking (P = .02), immunosuppressive medication (P = .02), and interactions terms for history of pneumonia * chronic pulmonary disease (P = .02), sex * immunosuppressive medication (P = .03), and chronic nephropathy * history of stroke (P = .03), CHD (P = .01), and immunosuppressive medication (P = .02). d Adjusted for age (P < .001), sex (P < .001), influenza vaccine status (P = .72), history of CAD (P < .001), history of stroke (P = .003), CHD (P < .001), diabetes mellitus (P < .001), hypertension (P = .004), and smoking (P = .007). e Adjusted for age (P = .07), sex (P = .02), influenza vaccine status (P = .78), history of CAD (P = .02), CHD (P < .001), and smoking as confounder (P < .45). f Adjusted for age (P < .001), sex (P = .11), influenza vaccine status (P = .71), history of CAD (P < .001), history of stroke (P < .001), diabetes mellitus (P < .001), hypertension as confounder (P = .32), smoking as confounder (P = .07), and interactions terms for log(time) * history of stroke (P < .001). g Adjusted for age (P = .68), sex (P = .95), influenza vaccine status (P = .83), CAD (P = .006), chronic nephropathy (P = .003), and dementia (P = .03).
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In the primary analyses, PPV23 vaccination did not substantially alter the risk of CAP (hazard ratio [HR], 0.94 [95% CI, 0.80-1.12]; P = .51), AMI (HR, 1.01 [95% CI, 0.82-1.25]; P = .92), or ischemic stroke (HR, 1.03 [95% CI, 0.83-1.28]; P = .81). After propensity and multivariate adjustments, PPV23 vaccination remained unassociated with the outcomes studied ( Table 2) .
Discussion | Our data do not support a cardiovascular protective role of PPV23 and refute prior data reporting a protective effect in our interim analysis. 4 Our findings show an increased short-term risk of acute thrombotic events among patients with CAP (2.8% and 0.7% of them developed AMI or ischemic stroke within 30 days after a CAP diagnosis, respectively), but vaccination did not reduce these risks.
The major strengths of this study were its populationbased design and the validation of outcome events by checking clinical records. The main limitation is that vaccination status was not randomized. We used rigorous methods to adjust for the propensity for vaccination and further adjusted for underlying conditions in multivariate analyses; however, as with all observational studies, a residual confounding cannot be completely excluded. Those individuals who had received PPV23 more than 5 years ago were considered to be unvaccinated. It is possible that some of these individuals could have a certain degree of antibody immunity that was not considered; however, a possible bias is unlikely considering that vaccination did not seem to be effective in more recent vaccinated subjects.
In conclusion, we found that the PPV23 does not provide any clinically relevant benefit against overall CAP, AMI, or stroke among the general population old than 60 years. More effective antipneumococcal vaccination strategies (eg, using conjugated and/or protein-based pneumococcal vaccines) 5, 6 for adults are needed.
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Indoor Tanning Among Young Non-Hispanic White Females
Indoor tanning is associated with an increased risk of skin cancer, especially among frequent users and those initiating use at a young age. 1, 2 Indoor tanning before age 35 years increases melanoma risk by 59% to 75%, 1 while use before age 25 years increases nonmelanoma skin cancer risk by 40% to 102%. 2 Moreover, melanoma risk increases by 1.8% with each additional tanning session per year. 1 Melanoma incidence rates are steadily increasing, especially among young non-Hispanic white females, which may be due, in part, to indoor tanning. 1, 3 Currently, prevalence estimates of indoor tanning among this population are limited. Therefore, we examined the prevalence of indoor tanning and frequent indoor tanning (≥10 times) using nationally representative data among non-Hispanic white female high school students and adults ages 18 to 34 years.
Methods | We used data from the 2011 national Youth Risk Behavior Survey (YRBS) of high school students and the 2010 National Health Interview Survey (NHIS) for adults aged 18 to 34 years. We estimated the prevalence of indoor tanning and frequent indoor tanning, overall and by age and US census region. Indoor tanning was defined as using an indoor tanning device (eg, a sunlamp, sunbed, or tanning booth, not including a spray-on tan) at least 1 time during the 12 months before each survey. Frequent indoor tanning was defined as using an indoor tanning device at least 10 times during the same pe-
